[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
A comprehensive review of protein kinase inhibitors for cancer therapy
R Kannaiyan, D Mahadevan - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The lancet …, 2016 - thelancet.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations
D Koenig, S Savic Prince, SI Rothschild - Cancers, 2021 - mdpi.com
Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
[HTML][HTML] Lung cancer in never smokers—the East Asian experience
F Zhou, C Zhou - Translational lung cancer research, 2018 - ncbi.nlm.nih.gov
Approximately one third of all lung cancer patients in East Asia are never-smokers.
Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing …
Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing …
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung …
BC Creelan, TC Yeh, SW Kim, N Nogami… - British journal of …, 2021 - nature.com
Background EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour
proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab …
proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …